185 related articles for article (PubMed ID: 22790636)
21. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
[No Abstract] [Full Text] [Related]
22. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
[TBL] [Abstract][Full Text] [Related]
23. Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Igarashi T; Ogura M; Itoh K; Taniwaki M; Ando K; Kuroda Y; Yamamoto K; Uike N; Tomita A; Nagai H; Kurosawa M; Mori S; Nawano S; Terauchi T; Ohashi Y; Tobinai K
Int J Hematol; 2016 Dec; 104(6):700-708. PubMed ID: 27714587
[TBL] [Abstract][Full Text] [Related]
24. Plexiform neurolymphomatosis.
Denays R; Baudrez V; Abouhamad P; Derème T; Milbouw G; Hermanne JP
Rev Neurol (Paris); 2016; 172(4-5):328-30. PubMed ID: 27117434
[No Abstract] [Full Text] [Related]
25. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
Griffiths R; Gleeson M; Reyes C; Knopf K; Danese M
Am J Hematol; 2010 Dec; 85(12):963-7. PubMed ID: 20981680
[No Abstract] [Full Text] [Related]
26. Glomerular infiltration by intravascular large B-cell lymphoma.
Tian C; Wang X; Zhang Y
Br J Haematol; 2016 Sep; 174(6):833. PubMed ID: 27391281
[No Abstract] [Full Text] [Related]
27. New concepts in treatment approaches and prognostic factors in aggressive NHL.
Shipp M
Clin Adv Hematol Oncol; 2006 Feb; 4(2):107-9. PubMed ID: 16728917
[No Abstract] [Full Text] [Related]
28. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
29. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
30. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma.
Tholstrup D; de Nully Brown P; Jurlander J; Hansen M
Eur J Haematol; 2007 Aug; 79(2):100-6. PubMed ID: 17608712
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large B-cell lymphoma.
Ng AK
Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K;
Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902
[TBL] [Abstract][Full Text] [Related]
36. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
37. Primary mediastinal large B-cell lymphoma.
Ergul SM; Lal A; Afri L; Frei-Lahr D
South Med J; 2002 Sep; 95(9):1005-7. PubMed ID: 12356098
[TBL] [Abstract][Full Text] [Related]
38. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
39. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
40. A blind skin biopsy diagnosing an intravascular large B-cell lymphoma.
Deschamps L; Signate A; Delaunay C; Morales I; Warter A; Smadja D; Derancourt C
Eur J Dermatol; 2011; 21(1):114-5. PubMed ID: 21233067
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
